OBN BioTuesday: Spotlight on the latest R&D for Neurodegenerative Diseases.

Compass Executives is delighted to announce that Senior Associate Andrea Litovszky will be attending the OBN BioTuesday: Spotlight on the latest R&D for Neurodegenerative Diseases in Oxford on 17th October 2023. 

About BioTuesday

A spotlight on the latest R&D for Neurodegenerative Diseases

Neurodegenerative disease impacts almost 50 million people globally, and during the past decades, there has been a surge in research interest, funding, and clinical trials to support the development of treatments for the most prevalent neurodegenerative diseases including Alzheimer’s and Parkinson’s. 

2022 was an important landmark in Alzheimer’s disease with FDA approvals for two amyloid immunotherapies, Aducanumab and Lecanemab, but despite this progress, therapies to prevent or decrease disease progression and restore neuronal function remain a challenge and an ongoing focus in both research and clinical practice.

This edition of our BioTuesday event aims to shine a light on the most recent R&D in both diagnostics and treatment of a range of neurodegenerative diseases and will feature an academic update along with presentations from some of the most exciting companies working in this space from the Oxfordshire region.

Agenda

• 18.00 – 18.30: Guest arrivals and networking
• 18.30 – 19.00: Welcome from Ipsen, and Keynote presentation from Brent Ryan, Research Lecturer, Department of Physiology, Anatomy & Genetics, University of Oxford​
• 19.00 – 20.00: R&D Showcase Presentations:

– Peter Hamley, CSO, Samsara Therapeutics​

– Baroness Susan Greenfield CBE. CEO and Founder, Neuro-Bio​

– Francesca Cordeiro, Founder and Director, Novai​

– Fraser Murray, CEO, ​Pheno Therapeutics​

• 20.00 – 20.30: Audience & Presenter Q&A
• 20.30 – 21.30: Networking

Further Information

To find out more about OBN BioTuesday, click here.

To view a complete list of events, seminars, awards and conferences Compass Executives are attending this year, please click here.